Multicentric Randomised Trial for Resectable Gastric Cancer
Status:
Recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
The CRITICS-II trial aims to identify the optimal preoperative regimen in resectable gastric
cancer by comparing three investigational treatment arms: chemotherapy vs. chemotherapy and
subsequent chemoradiotherapy vs. chemoradiotherapy. The rationale behind this trial design is
based on the following concepts:
- Preoperative treatment is associated with better patient compliance than postoperative
regimens
- Preoperative treatment increases the likelihood of disease downsizing/downstaging and
radical R0 resections
- Preoperative paclitaxel/carboplatin-based concurrent chemoradiotherapy and DOC
chemotherapy are effective, feasible and safe regimens